« Return to News | Drug Sponsors

Painless Growth?

Monday, October 9, 2006 07:21 AM

Big Pharma continues to expand into the vaccine market as Pfizer purchased privately owned PowderMed this week, hoping for an ouch-free entry into this segment. The vaccine market is suddenly looking golden to Big Pharma when just a few years ago it seemed that most drugmakers wouldn’t go near vaccines.

Now with government encouragement and the promise of fairly predictable growth, Big Pharma is into vaccines in a big way. With U.K.-based PowerMed, Pfizer is getting a company developing needle-free, DNA-based vaccines.

PowderMed’s technology shoots— at supersonic speed—DNA-coated gold particles into the skin. Using DNA-based vaccines could help replace old-style vaccines cultured in chicken eggs, for example. Manufacturing costs are one of the biggest roadblocks to vaccine profitability.

PowderMed is currently testing its technology in six trials for influenza and other viral diseases.

Pfizer isn’t the only Big Pharma company injecting itself into vaccine markets. In 2005, Novartis bought California-based biotech Chiron for $5.1 billion and GlaxoSmithKline plans to launch at least four new vaccines in the next five years. Glaxo also recently acquired ID Biomedical of Canada.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.